Eli Lilly’s diabetes drug Mounjaro (tirzepatide) has received support from Britain’s healthcare cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE).
NICE, in draft final guidance, recommends Mounjaro as a good option for patients with poorly controlled type 2 diabetes, estimating that around 180,000 individuals could benefit from this new treatment.
Mounjaro is also under consideration for its potential to treat obesity, with a U.S. decision on its use for weight loss expected later this year.
Eli Lilly’s diabetes drug Mounjaro approved by UK “NICE”
The positive outlook for Mounjaro has led to a surge in Eli Lilly’s share price, as investors anticipate it becoming a blockbuster drug upon approval.
The final guidance from NICE is set to be published on October 11, and the drug will be made available in the UK’s National Health Service (NHS) within 90 days following this announcement.
NICE is the governmental agency responsible for determining whether medicines should be used in the NHS.
Earlier in July, NICE had requested additional data from Eli Lilly regarding the drug’s benefits.
This decision from NICE comes amidst national shortages of Novo Nordisk’s Ozempic, which belongs to the same drug class as Mounjaro and is approved in Britain for the treatment of type 2 diabetes.